JP2024501403A5 - - Google Patents
Info
- Publication number
- JP2024501403A5 JP2024501403A5 JP2023532452A JP2023532452A JP2024501403A5 JP 2024501403 A5 JP2024501403 A5 JP 2024501403A5 JP 2023532452 A JP2023532452 A JP 2023532452A JP 2023532452 A JP2023532452 A JP 2023532452A JP 2024501403 A5 JP2024501403 A5 JP 2024501403A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody according
- seq
- bispecific antibody
- sequence
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20213166.0 | 2020-12-10 | ||
| EP20213166 | 2020-12-10 | ||
| PCT/EP2021/085079 WO2022122973A1 (en) | 2020-12-10 | 2021-12-09 | Antibodies that bind gamma-delta t cell receptors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024501403A JP2024501403A (ja) | 2024-01-12 |
| JP2024501403A5 true JP2024501403A5 (enExample) | 2024-12-17 |
Family
ID=73793117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023532452A Pending JP2024501403A (ja) | 2020-12-10 | 2021-12-09 | ガンマ－デルタｔ細胞受容体に結合する抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230303694A1 (enExample) |
| EP (1) | EP4259660A1 (enExample) |
| JP (1) | JP2024501403A (enExample) |
| KR (1) | KR20230157933A (enExample) |
| CN (1) | CN116888153A (enExample) |
| AU (1) | AU2021395439A1 (enExample) |
| CA (1) | CA3200826A1 (enExample) |
| IL (1) | IL303045A (enExample) |
| MX (1) | MX2023006832A (enExample) |
| WO (1) | WO2022122973A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230042035A (ko) | 2020-07-08 | 2023-03-27 | 라바 테라퓨틱스 엔.브이. | Psma와 감마-델타 t 세포 수용체에 결합할 수 있는 항체 |
| EP4292610A1 (en) * | 2022-06-15 | 2023-12-20 | LAVA Therapeutics N.V. | Variant antibodies that bind gamma-delta t cell receptors |
| EP4292609A1 (en) | 2022-06-15 | 2023-12-20 | LAVA Therapeutics N.V. | Compositions comprising antibodies that bind gamma-delta t cell receptors |
| EP4688851A1 (en) | 2023-03-27 | 2026-02-11 | LAVA Therapeutics N.V. | Nectin-4 binding agents and methods of use |
| WO2025012118A2 (en) | 2023-07-07 | 2025-01-16 | LAVA Therapeutics N.V. | 5t4 binding agents and methods of use |
| WO2025024780A1 (en) | 2023-07-27 | 2025-01-30 | LAVA Therapeutics N.V. | Antibodies that bind gamma-delta t cell receptors for the treatment of cancer |
| WO2025128615A1 (en) * | 2023-12-12 | 2025-06-19 | Seagen Inc. | Multispecific egfr antibodies and use in the treatment of cancer |
| TW202535922A (zh) * | 2023-12-18 | 2025-09-16 | 美商思進公司 | 治療ｅｇｆｒ突變癌症之方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100081792A1 (en) | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
| CA2631184A1 (en) | 2005-11-28 | 2007-05-31 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| WO2010059315A1 (en) | 2008-11-18 | 2010-05-27 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
| WO2010111625A1 (en) | 2009-03-27 | 2010-09-30 | Zymogenetics, Inc. | Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination |
| KR101224468B1 (ko) | 2009-05-20 | 2013-01-23 | 주식회사 파멥신 | 신규한 형태의 이중표적항체 및 그 용도 |
| CN103261220B (zh) | 2010-08-16 | 2016-06-15 | 诺夫免疫股份有限公司 | 用于生成多特异性和多价抗体的方法 |
| US9248181B2 (en) | 2012-04-20 | 2016-02-02 | Merus B.V. | Methods and means for the production of Ig-like molecules |
| DK2924052T3 (da) | 2012-11-21 | 2019-09-30 | Pharmabcine Inc | Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme |
| DK3129404T3 (da) | 2014-04-10 | 2026-04-20 | Lava Therapeutics N V | Immunglobuliner, der binder humane vgamma9vdelta2-t-cellereceptorer |
| AU2019344300A1 (en) | 2018-09-19 | 2021-04-22 | LAVA Therapeutics N.V. | Dual acting CD1D immunoglobulin |
| CN113993893A (zh) * | 2019-02-01 | 2022-01-28 | 拉法医疗有限公司 | 新cd40结合抗体 |
| EP3792283A1 (en) | 2019-09-16 | 2021-03-17 | Lava Therapeutics B.V. | Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies |
-
2021
- 2021-12-09 CA CA3200826A patent/CA3200826A1/en active Pending
- 2021-12-09 MX MX2023006832A patent/MX2023006832A/es unknown
- 2021-12-09 EP EP21824387.1A patent/EP4259660A1/en active Pending
- 2021-12-09 WO PCT/EP2021/085079 patent/WO2022122973A1/en not_active Ceased
- 2021-12-09 KR KR1020237023004A patent/KR20230157933A/ko active Pending
- 2021-12-09 CN CN202180090574.0A patent/CN116888153A/zh active Pending
- 2021-12-09 AU AU2021395439A patent/AU2021395439A1/en active Pending
- 2021-12-09 IL IL303045A patent/IL303045A/en unknown
- 2021-12-09 JP JP2023532452A patent/JP2024501403A/ja active Pending
-
2023
- 2023-06-09 US US18/332,165 patent/US20230303694A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024501403A5 (enExample) | ||
| CN102369214B (zh) | 三价、双特异性抗体 | |
| CN107922486B (zh) | 异源二聚体多特异性抗体形式 | |
| JP2023532807A5 (enExample) | ||
| US20170349667A1 (en) | C-met antibody combinations | |
| JP2019501883A5 (enExample) | ||
| JP2021522162A5 (enExample) | ||
| CN106397598B (zh) | 多价多特异性抗体及免疫杂合蛋白的表达和制备方法 | |
| JP2021510521A5 (enExample) | ||
| JP2018537966A5 (enExample) | ||
| JP2018502050A5 (enExample) | ||
| JP2018522541A5 (enExample) | ||
| WO2013064701A2 (en) | Bispecific antibodies and methods for isolating same | |
| JP2021533159A5 (enExample) | ||
| CN106397599B (zh) | 二价双特异性抗体杂交蛋白的表达和制备方法 | |
| JP2023532129A5 (enExample) | ||
| JP2020502233A5 (enExample) | ||
| JP2021512613A5 (enExample) | ||
| JP7657591B2 (ja) | 二重特異性抗原結合コンストラクト | |
| JP2024508808A5 (enExample) | ||
| JP2025504909A5 (enExample) | ||
| JP2022521305A (ja) | 抗ｐｄ－ｌ１抗体及びその使用 | |
| KR20210107747A (ko) | 항체 융합 단백질, 이의 제조 방법 및 이의 적용 | |
| JP2024507937A5 (enExample) | ||
| JPWO2022102768A5 (enExample) |